Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 19 2 2025 04 20 193 197 Mekni Sabrine Faculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia Ben Hana Faculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia Noureddine Litaiem Faculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia Kanoun Yosra Faculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia Torjemane Lamia Faculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia Belloumi Dorra Faculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia Ben Insaf Faculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia Ouerghi Rihab Faculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia Turki Ines Faculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia Chaabane Anna Faculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia Ben Tarek Faculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia Ben Nour Faculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia 2024 08 27 2025 03 02 Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL) and is characterized by a heterogeneous clinical course and variant stage involvement. Indolent disease is usually observed in its early stages. However, the treatment options for patients with advanced MF are limited and have poor outcomes. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potential curative treatment for refractory cases. Here, we describe the case of a 34-year-old man who was diagnosed with MF at an advanced stage. Eight months before allo-HSCT, the patient received six courses of polychemotherapy based on cyclophosphamide, doxorubicin, vincristine, and prednisolone, which were administered every three weeks. A partial response was obtained. He underwent allo-HSCT after a myeloablative conditioning regimen and remained in complete remission (CR) for 26 months posttransplantation. Our findings confirm that allo-HSCT can be a curative option for refractory MF. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2310 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2310/1085